Phase 2 Clinical Trial of GH001 in Postpartum Depression
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15
female participants with clinically diagnosed postpartum depression (PPD) will be included in
this study. The participants will receive an individualized dosing regimen (IDR) with at
least one and up to three doses of GH001 administered within a single day.